Zobrazeno 1 - 10
of 216
pro vyhledávání: '"Eline Menu"'
Autor:
Niels Vandewalle, Nathan De Beule, Ann De Becker, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Karine Breckpot, Nick Devoogdt, Kim De Veirman
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-20 (2024)
Abstract Until recently, treatment options for patients diagnosed with Acute Myeloid Leukemia (AML) were limited and predominantly relied on various combinations, dosages, or schedules of traditional chemotherapeutic agents. Patients with advanced ag
Externí odkaz:
https://doaj.org/article/b82af3f652d947baaa454fecce5ba893
Autor:
Arne Van der Vreken, Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Karine Breckpot, Eline Menu
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-17 (2024)
Abstract CAR T cells are widely applied for relapsed hematological cancer patients. With six approved cell therapies, for Multiple Myeloma and other B-cell malignancies, new insights emerge. Profound evidence shows that patients who fail CAR T-cell t
Externí odkaz:
https://doaj.org/article/022f5eaf712e4b80971a4066ab9cab61
Autor:
Yanmeng Wang, Niels Vandewalle, Kim De Veirman, Karin Vanderkerken, Eline Menu, Elke De Bruyne
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-17 (2024)
Abstract Multiple Myeloma (MM), a cancer of terminally differentiated plasma cells, is the second most prevalent hematological malignancy and is incurable due to the inevitable development of drug resistance. Intense protein synthesis is a distinctiv
Externí odkaz:
https://doaj.org/article/e5bf627c82af4b75bb7d189ce17c47ad
Autor:
Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Elke De Bruyne, Eline Menu, Nathan De Beule, Ann De Becker, Gamze Ates, Ann Massie, Tessa Kerre, Marie Törngren, Helena Eriksson, Karin Vanderkerken, Karine Breckpot, Ken Maes, Kim De Veirman
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Acute Myeloid Leukemia (AML) is a heterogeneous disease with limited treatment options and a high demand for novel targeted therapies. Since myeloid-related protein S100A9 is abundantly expressed in AML, we aimed to unravel the therapeutic i
Externí odkaz:
https://doaj.org/article/e3d2c809e45a47e385516477b86ed8c1
Autor:
Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger, Dirk Hose
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundImmunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (comb
Externí odkaz:
https://doaj.org/article/c65a30545a9545fdbf7aa6e375ae1aa6
Autor:
Inge Oudaert, Arne Van der Vreken, Anke Maes, Elke De Bruyne, Kim De Veirman, Karin Vanderkerken, Eline Menu
Publikováno v:
Experimental Hematology & Oncology, Vol 11, Iss 1, Pp 1-19 (2022)
Abstract Cancer cells are well-known for their capacity to adapt their metabolism to their increasing energy demands which is necessary for tumor progression. This is no different for Multiple Myeloma (MM), a hematological cancer which develops in th
Externí odkaz:
https://doaj.org/article/4cddb19e569c43b5afa9a732cb825f39
Autor:
Yanmeng Wang, Catharina Muylaert, Arne Wyns, Philip Vlummens, Kim De Veirman, Karin Vanderkerken, Esther Zaal, Celia Berkers, Jérome Moreaux, Elke De Bruyne, Eline Menu
Publikováno v:
Haematologica, Vol 109, Iss 1 (2023)
Multiple myeloma (MM) is the second most prevalent hematologic malignancy and is incurable because of the inevitable development of drug resistance. Methionine adenosyltransferase 2α (MAT2A) is the primary producer of the methyl donor S-adenosylmeth
Externí odkaz:
https://doaj.org/article/1df90703e61a4a2bb047a6e15e26973a
Autor:
Inge Oudaert, Hatice Satilmis, Philip Vlummens, Wouter De Brouwer, Anke Maes, Dirk Hose, Elke De Bruyne, Bart Ghesquière, Karin Vanderkerken, Kim De Veirman, Eline Menu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-17 (2022)
Abstract Background Multiple myeloma (MM) remains an incurable cancer despite advances in therapy. Therefore, the search for new targets is still essential to uncover potential treatment strategies. Metabolic changes, induced by the hypoxic bone marr
Externí odkaz:
https://doaj.org/article/e8e263e6af5e473fb6e4e31c1ab28d5d
Autor:
Marie Törngren, Rong Fan, Eline Menu, Helena Eriksson, Karin Vanderkerken, Andrew Chantry, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Holly Evans, Nathan De Beule, Dirk Hose, Ken Maes, Karine Breckpot, Kim De Veirman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients. However, therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid cells. S100A9 wa
Externí odkaz:
https://doaj.org/article/d2125622a63f49eba73f4bc280a4cd85
Publikováno v:
BMC Biology, Vol 19, Iss 1, Pp 1-17 (2021)
Abstract Background Hematopoietic stem and progenitor cell (HSPC) subsets in mice have previously been studied using cell surface markers, and more recently single-cell technologies. The recent revolution of single-cell analysis is substantially tran
Externí odkaz:
https://doaj.org/article/00ce220ca4c44f8784f663fd174658fb